← SynDRA
Ro-154513
SynDRA canonical compound SYN0000053 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | GABRA5 |
|---|
| Mechanism of action | GABA benzodiazepine site receptor inverse agonist |
|---|
All known targets
- GABRA1
- GABRA2
- GABRA3
- GABRA5
- GABRA4
- GABRA6
- GABRB2
- GABRG2
- GABRG3
Mechanisms of action (all sources)
- GABA benzodiazepine site receptor inverse agonist
- GABRA1 INVERSE AGONIST
- GABRA2 INVERSE AGONIST
- GABRA3 INVERSE AGONIST
- GABRA4 FULL AGONIST
- GABRA5 INVERSE AGONIST
- GABRA6 FULL AGONIST
- GABRG3 MODULATOR (ALLOSTERIC MODULATOR)
- GABRB2 INHIBITOR
- GABRA5 INHIBITOR
- GABRA1 INHIBITOR
- GABRG2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALDH1A1
- ALOX15
- APEX1
- HDAC6
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- GABRB3
- GBRA2
- GBRA3
- GBRA4
- GBRA5
- GBRA6
Cross-references
Synonyms
- [3H]Ro154513
- Ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
- Ro 15-4513
- Ro15-4513
- UNII-S5XGL82O5Y
- S5XGL82O5Y
- Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate
- Ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
- Ethyl 8-azido-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate
- Ro-15-4513
- Ro 154513
- Azidomazenil
- GTPL4296
- GTPL4365
- orb1706701
- SCHEMBL15009603
- SCHEMBL29421379
- BDBM26267
- CHEBI:93452
- HMS3268D11
- HMS3413A05
- HMS3677A05
- HMS3752C17
- RDA91765
- EX-A14651
- MFCD00078598
- PDSP1_001777
- PDSP2_001760
- AKOS024456901
- [3H]Ro15-4513
- NCGC00092292-01
- Ro15-4513?
- DA-77499
- MS-24865
- HY-103476
- CS-0027980
- G12275
- T16775
Look up Ro-154513 in the interactive SynDRA portal →